Genky DrugStores Co., Ltd.

TSE:9267 Voorraadrapport

Marktkapitalisatie: JP¥92.2b

Genky DrugStores Toekomstige groei

Future criteriumcontroles 2/6

Genky DrugStores is forecast to grow earnings and revenue by 8.6% and 8.3% per annum respectively. EPS is expected to grow by 8.6% per annum. Return on equity is forecast to be 13.3% in 3 years.

Belangrijke informatie

8.6%

Groei van de winst

8.6%

Groei van de winst per aandeel

Consumer Retailing winstgroei12.8%
Inkomstengroei8.3%
Toekomstig rendement op eigen vermogen13.3%
Dekking van analisten

Low

Laatst bijgewerkt28 Oct 2024

Recente toekomstige groei-updates

Genky DrugStores Co., Ltd. (TSE:9267) Just Reported And Analysts Have Been Lifting Their Price Targets

Oct 30
Genky DrugStores Co., Ltd. (TSE:9267) Just Reported And Analysts Have Been Lifting Their Price Targets

Earnings Update: Here's Why Analysts Just Lifted Their Genky DrugStores Co., Ltd. (TSE:9267) Price Target To JP¥7,600

Apr 27
Earnings Update: Here's Why Analysts Just Lifted Their Genky DrugStores Co., Ltd. (TSE:9267) Price Target To JP¥7,600

Recent updates

Genky DrugStores Co., Ltd. (TSE:9267) Just Reported And Analysts Have Been Lifting Their Price Targets

Oct 30
Genky DrugStores Co., Ltd. (TSE:9267) Just Reported And Analysts Have Been Lifting Their Price Targets

What Genky DrugStores Co., Ltd.'s (TSE:9267) 28% Share Price Gain Is Not Telling You

Aug 07
What Genky DrugStores Co., Ltd.'s (TSE:9267) 28% Share Price Gain Is Not Telling You

Earnings Update: Here's Why Analysts Just Lifted Their Genky DrugStores Co., Ltd. (TSE:9267) Price Target To JP¥7,600

Apr 27
Earnings Update: Here's Why Analysts Just Lifted Their Genky DrugStores Co., Ltd. (TSE:9267) Price Target To JP¥7,600

Return Trends At Genky DrugStores (TSE:9267) Aren't Appealing

Mar 07
Return Trends At Genky DrugStores (TSE:9267) Aren't Appealing

Winst- en omzetgroeiprognoses

TSE:9267 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
6/30/2027240,8508,610-52N/A2
6/30/2026221,7007,851-91N/A2
6/30/2025203,9007,210-818N/A2
9/20/2024188,0396,464N/AN/AN/A
6/20/2024184,8606,3242,81513,256N/A
3/20/2024181,4415,907N/AN/AN/A
12/20/2023177,1525,580-1,51210,740N/A
9/20/2023173,3175,106N/AN/AN/A
6/20/2023169,0594,764-1,1558,773N/A
3/20/2023165,0784,668N/AN/AN/A
12/20/2022162,2724,559-1,1239,177N/A
9/20/2022158,1344,290N/AN/AN/A
6/20/2022154,6394,420-4,4316,076N/A
3/20/2022152,6924,484N/AN/AN/A
12/20/2021149,5004,527-2408,809N/A
9/20/2021146,4194,775N/AN/AN/A
6/20/2021142,3764,8313,12112,075N/A
3/20/2021140,8514,449N/AN/AN/A
12/20/2020136,3904,4552,33811,396N/A
9/20/2020130,1733,565N/AN/AN/A
6/20/2020123,6032,755-3,5947,411N/A
3/20/2020113,7072,268N/AN/AN/A
12/20/2019108,3051,958-7,8612,946N/A
9/20/2019105,8322,334N/AN/AN/A
6/20/2019103,8972,697-6,4224,300N/A
3/20/2019101,9483,275N/AN/AN/A
12/20/2018100,1673,179-3,2574,694N/A
9/20/201897,7533,178N/AN/AN/A
6/20/201894,8693,118N/A5,365N/A
3/20/201892,0312,972N/AN/AN/A
12/20/201789,3012,880N/A6,866N/A
9/20/201786,3792,867N/AN/AN/A
6/20/201783,3992,845N/A5,238N/A
3/20/201780,8792,603N/AN/AN/A
12/20/201678,6402,462N/A2,805N/A
9/20/201676,1702,223N/AN/AN/A
6/20/201673,4951,901N/A2,695N/A
3/20/201670,4261,643N/AN/AN/A
12/20/201567,7611,740N/A3,498N/A
9/20/201565,4131,743N/AN/AN/A
6/20/201563,1431,761N/A4,758N/A
3/20/201561,5241,819N/AN/AN/A
12/20/201460,8111,635N/A3,767N/A
9/20/201459,8531,452N/AN/AN/A
6/20/201457,9491,171N/A3,662N/A
3/20/201456,365944N/AN/AN/A
12/20/201354,710768N/A3,446N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 9267's forecast earnings growth (8.6% per year) is above the savings rate (0.3%).

Winst versus markt: 9267's earnings (8.6% per year) are forecast to grow slower than the JP market (8.9% per year).

Hoge groeiwinsten: 9267's earnings are forecast to grow, but not significantly.

Omzet versus markt: 9267's revenue (8.3% per year) is forecast to grow faster than the JP market (4.2% per year).

Hoge groei-inkomsten: 9267's revenue (8.3% per year) is forecast to grow slower than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: 9267's Return on Equity is forecast to be low in 3 years time (13.3%).


Ontdek groeibedrijven